Shire announced the launch of Natpara (parathyroid hormone) for injection indicated as adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism.

Natpara is a bioengineered replica of human parathyroid hormone that raises serum calcium by increasing renal tubular calcium reabsorption, increasing intestinal calcium absorption (ie, by converting 25 OH vitamin D to 1,25 OH2 vitamin D), and by increasing bone turnover which releases calcium into the circulation.

Natpara is only available through a Risk Evaluation and Mitigation Strategy (REMS) Program by a limited number of specialty pharmacies. Under the Natpara REMS Program, only certified healthcare providers can prescribe, and only certified pharmacies can dispense the product.

Natpara is supplied in 25-mcg, 50-mcg, 75-mcg and 100-mcg strength cartridges in 2-count packages.

The FDA approved Natpara in January 2015. 

For more information call (855) NAT-PARA or visit Natpara.com.

This article originally appeared on MPR